Can-Fite BioPharma
Latest round
- Series B
Last raised
- Jun 2003
Total raised
- $12M
Investors
- 5
About Can-Fite BioPharma
Based in Israel, Can-Fite BioPharma Ltd.Can-Fite BioPharma Ltd. is engaged in the development of proprietary drug candidates. The company is headquartered in Petah Tikva, Israel. Motti Farbstein serves as the CEO.Can-Fite BioPharma primarily offers a range of proprietary drug candidates that leverage its advanced technology platform, focusing on the A3 adenosine receptor (A3AR) as a therapeutic target. The company's core products include Piclidenoson (CF101), which is in development for the treatment of psoriasis, and Namodenoson (CF102), aimed at addressing liver cancer and non-alcoholic steatohepatitis (NASH). These products are designed to modulate inflammatory and cancer pathways by binding with high affinity to A3AR, which is predominantly expressed in pathological cells while showing low expression in normal tissues. Can-Fite's drug candidates are actively being developed in clinical phases II and III, targeting a global clientele that includes pharmaceutical partners and healthcare providers across regions such as Canada, Spain, Switzerland, Austria, Korea, and China.Can-Fite BioPharma's revenue structure is primarily driven by strategic partnerships and licensing agreements for its drug candidates. The company reported revenue of USD 810,000 in 2022, with an EBITDA of USD -10,082,000. Can-Fite has established collaborations with multiple pharmaceutical entities, such as Cipher Pharmaceuticals in Canada and Chong Kun Dang Pharmaceutical in Korea, to commercialize its products in various geographical markets. Transactions typically occur through licensing arrangements, where Can-Fite receives upfront payments and potential royalties based on future sales of its proprietary drugs.Can-Fite BioPharma is focused on advancing its drug candidates through clinical trials, with plans to launch new products in the coming years. The company intends to expand into new markets, particularly in North America and Europe, aiming to establish a stronger presence by 2025.00 mn will be utilized to support these initiatives, including scaling operations and enhancing its research and development capabilities.
Who invested in Can-Fite BioPharma
5 investors across 2 rounds
See all investors in Can-Fite BioPharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Can-Fite BioPharma
Who invested in Can-Fite BioPharma?
Can-Fite BioPharma has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Can-Fite BioPharma raised?
Can-Fite BioPharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Can-Fite BioPharma last raise money?
Can-Fite BioPharma's most recent round on record is a Series B, in Jun 2003.
What does Can-Fite BioPharma do?
Based in Israel, Can-Fite BioPharma Ltd.
Where is Can-Fite BioPharma headquartered?
Can-Fite BioPharma is headquartered in Petah Tikva, Israel.
Which VCs invest in companies like Can-Fite BioPharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Can-Fite BioPharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Can-Fite BioPharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.